Cancer Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Cancer Immunotherapy stocks.

Cancer Immunotherapy Stocks Recent News

Date Stock Title
Nov 1 ZYME Zymeworks Q4 2024 Earnings Preview
Nov 1 ARGX argenx downgraded at Baird as shares get pricey
Nov 1 ZYME Zymeworks drops as Wells Fargo cuts on valuation
Nov 1 ZYME Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
Nov 1 ARGX argenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Challenges
Nov 1 ZYME Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation
Nov 1 ZYME Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Oct 31 ZYME Zymeworks GAAP EPS of -$0.39 in-line, revenue of $16M misses by $1.85M
Oct 31 ZYME Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 31 IOVA Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Oct 31 ARGX Here’s Why You Should Hold Argenx SE (ARGX)
Oct 31 ARGX Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31 ARGX argenx SE (ARGX) Q3 2024 Earnings Call Transcript
Oct 31 ARGX argenx SE 2024 Q3 - Results - Earnings Call Presentation
Oct 31 ARGX Argenx SE reports Q3 results
Oct 31 ARGX argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 30 ZYME Zymeworks Q3 2024 Earnings Preview
Oct 30 ARGX Argenx SE Q3 2024 Earnings Preview
Oct 30 XLO Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Oct 28 IBRX PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Cancer Immunotherapy

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules (e.g. carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.

Browse All Tags